When Roche bought Genentech in March, layoffs were expected, and now the company has begun downsizing at Genentech’s South San Francisco headquarters. So far the cuts have affected "less than one percent" of Genentech's 8,250 Bay Area employees, the company told the San Francisco Chronicle.

The reductions, which are occurring through a combination of voluntary buyouts and layoffs, focus on late-stage drug development and corporate administration, the Chronicle reported. There will be “little to no” job loss in manufacturing and all six of the Genentech’s manufacturing and distribution sites will stay open.

Chronicle report